Table 1—

Characteristics of the 449 study participants by age-group at diagnosis

Age-group at diagnosis (years)
P value
0–45–910–1415–19
n (%)50 (11.1)159 (35.4)189 (42.1)51 (11.4)
Diabetes duration (months)7.7 ± 2.77.6 ± 2.77.6 ± 2.77.3 ± 2.50.3
Insulin dose (units · kg−1 · day−1)0.6 ± 0.60.6 ± 0.20.6 ± 0.40.5 ± 0.20.6
FCP (ng/ml)0.35 ± 0.260.52 ± 0.471.01 ± 1.091.69 ± 1.53<0.0001
A1C (%)8.0 ± 1.07.5 ± 1.37.5 ± 1.56.9 ± 1.40.002
Fasting blood glucose183.4 ± 85.6164.8 ± 76.7173.8 ± 80.0155.2 ± 65.00.5
GAD65 titer0.61 ± 1.440.55 ± 0.950.43 ± 0.540.40 ± 0.450.1
IA2 titer0.47 ± 0.410.58 ± 0.520.57 ± 0.430.38 ± 0.450.2
% 1:2 DA positive44:561:4945:5563:370.5
  • Data are means ± SD unless otherwise indicated. P values are from testing the correlation between each variable and continuous age at diagnosis; for %1:2 diabetes antoantibody (DA) positive, Spearman’s rank correlation, using continuous age at diagnosis vs. the number of positive DAs, was used to assess significance.